News
Tocilizumab linked to refractory uveitis improvements in some JIA patients
MADRID – Tocilizumab was associated with improved vision in a substantial proportion of 22 children with juvenile...
News
Emapalumab produces major responses in macrophage activation syndrome
MADRID – In systemic juvenile idiopathic arthritis complicated by MAS, new therapy produces rapid complete responses.
News
Obesity might be targetable driver of psoriatic arthritis progression
MADRID – Two studies show how obesity correlates with greater psoriatic arthritis disease activity and disability and how substantial weight loss...
News
Despite advances, imaging of axSpA remains an adjunctive tool
MADRID – Supported by data, experts agree that diagnosis and assessment of axSpA is aided but not dependent on imaging.
News
Experts agree on routine lung disease screening in systemic sclerosis
MADRID – Expert management recommendations for interstitial lung disease in systemic sclerosis advise matching frequency of screening to risk.
News
Checkpoint inhibitor–induced rheumatic complications have unique features
MADRID – The phenotypic musculoskeletal complications of checkpoint inhibitors do not resemble other joint pathology.
Video
Retention rates comparable for biosimilars, original drug in spondyloarthritis
MADRID – One-year treatment data drawn from registries in five Scandinavian countries.
Video
Video program engages patients in treat-to-target concept
MADRID – Previous lack of awareness of this concept might be responsible for lack of adherence to therapy.
News
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapies
The new guidelines are tailored for rheumatologists, and address diagnosis and treatment.
News
Weight loss in knee OA patients sustained with liraglutide over 1 year
MADRID – After an intensive weight-loss program, liraglutide not only sustained but further improved weight loss.
Video
Patient selection important for osteoarthritis structural and symptom endpoints
MADRID – Dr. Philip G. Conaghan discusses the difficulties in reconciling structural and symptomatic endpoints in osteoarthritis trials.